BioLife Solutions Inc (NASDAQ:BLFS) VP James Mathers sold 2,500 shares of the stock in a transaction dated Thursday, July 11th. The stock was sold at an average price of $17.15, for a total value of $42,875.00. Following the transaction, the vice president now owns 19,884 shares of the company’s stock, valued at approximately $341,010.60. The transaction was disclosed in a filing with the SEC, which is available at this link.
James Mathers also recently made the following trade(s):
- On Tuesday, July 9th, James Mathers sold 2,500 shares of BioLife Solutions stock. The stock was sold at an average price of $17.94, for a total value of $44,850.00.
Shares of NASDAQ BLFS opened at $16.93 on Friday. The company has a market cap of $318.27 million, a PE ratio of 120.93 and a beta of 1.31. The firm has a 50-day moving average of $17.22. The company has a debt-to-equity ratio of 0.02, a current ratio of 14.50 and a quick ratio of 12.99. BioLife Solutions Inc has a fifty-two week low of $9.15 and a fifty-two week high of $26.35.
BioLife Solutions (NASDAQ:BLFS) last announced its quarterly earnings data on Thursday, May 9th. The medical equipment provider reported $0.03 earnings per share for the quarter, meeting the Thomson Reuters’ consensus estimate of $0.03. The company had revenue of $5.77 million during the quarter, compared to analysts’ expectations of $5.67 million. BioLife Solutions had a return on equity of 10.32% and a net margin of 17.01%. On average, sell-side analysts anticipate that BioLife Solutions Inc will post 0.12 earnings per share for the current fiscal year.
A number of research firms have issued reports on BLFS. ValuEngine upgraded XCel Brands from a “sell” rating to a “hold” rating in a report on Tuesday, July 9th. BidaskClub cut Weyco Group from a “sell” rating to a “strong sell” rating in a report on Saturday. Northland Securities increased their target price on Paycom Software from $215.00 to $275.00 and gave the stock an “outperform” rating in a report on Tuesday, July 9th. Zacks Investment Research cut ExlService from a “hold” rating to a “sell” rating in a report on Wednesday. Finally, Maxim Group set a $24.00 target price on BioLife Solutions and gave the stock a “buy” rating in a report on Wednesday, May 22nd. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and five have given a buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus target price of $17.80.
Several hedge funds and other institutional investors have recently made changes to their positions in BLFS. Cowen Prime Services LLC bought a new position in shares of BioLife Solutions in the 1st quarter valued at about $63,000. Signaturefd LLC bought a new position in shares of BioLife Solutions in the 1st quarter valued at about $161,000. GSA Capital Partners LLP grew its holdings in shares of BioLife Solutions by 21.1% in the 4th quarter. GSA Capital Partners LLP now owns 13,800 shares of the medical equipment provider’s stock valued at $166,000 after acquiring an additional 2,400 shares in the last quarter. Conestoga Capital Advisors LLC bought a new position in shares of BioLife Solutions in the 1st quarter valued at about $238,000. Finally, Weiss Multi Strategy Advisers LLC bought a new position in shares of BioLife Solutions in the 4th quarter valued at about $241,000. Institutional investors own 45.76% of the company’s stock.
BioLife Solutions Company Profile
BioLife Solutions, Inc develops, manufactures, and markets grade cell and tissue hypothermic storage and cryopreservation freeze media products for cells, tissues, and organs in the United States. Its products are serum-free and protein-free solutions, which are formulated to reduce preservation-induced cell damage and death.
Featured Story: What moving averages are used to define a golden cross?
Receive News & Ratings for BioLife Solutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioLife Solutions and related companies with MarketBeat.com's FREE daily email newsletter.